RDHL · RedHill Biopharma Ltd. · Metrics
Market Cap
$3.75M
Shares
8.89M
Volume · Oct 23
88.25K
Avg daily vol (3M)
2.04M
RDHL metrics
59 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$0.42
Market cap
$3.75M
Price action
20 metricsPrice change (1W)
-15.4%
Price change (30D)
-22.3%
Price change (3M)
-36.8%
Price change (6M)
-59.0%
Price change (YTD)
-59.0%
Price change (1Y)
-75.7%
Trailing year
Price change (5Y)
—
52-week high
$1.74
52-week low
$0.42
Change from 52-week high
-75.7%
Change from 52-week low
+0.0%
Annualized volatility
91.3%
Annualized volatility (3M)
115.1%
Beta
0.5
RSI (14D)
35.2
Price vs SMA 50
-27.1%
Price vs SMA 200
-49.5%
Avg volume (3M)
2.04M
Relative volume
0.1
Average dollar volume
$1.71M
Company
3 metricsSector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
8.89M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
—
FCF yield
-227.8%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
—
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2022-03-31
Profitability
9 metricsGross margin
—
Operating margin
-2,776.9%
Trailing 12 months
Net margin
-150.0%
Gross profit (TTM)
$6.16M
Operating profit (TTM)
−$8.68M
Net income (TTM)
−$2.40M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
-14.7%
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+294.8%
Year over year · more shares
Revenue CAGR (3Y)
-83.3%
Revenue CAGR (5Y)
-66.2%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
—
Return on assets
-9.1%
Debt / equity
—
Current ratio
0.3
EBITDA (TTM)
—
Free cash flow (TTM)
−$9.21M
Quick ratio
—
Interest coverage
-3.9
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$5.16M
Total assets
$26.27M
Total debt
—
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$9.20M
Capital expenditures (TTM)
$15,000
R&D (TTM)
$2.02M
SG&A (TTM)
—
Stock compensation (TTM)
$464,000
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
9 metrics13F filers
14
13F filer change QoQ
-2
Institutional ownership
3.6%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
-41.8%
Holder tenure
3.9
Price vs estimated holder cost
-33.5%
Ownership (registered funds)
1 metricsIndex-fund ownership
0.0%
Short interest
3 metricsShort interest
2.4%
Latest settlement · 1.6 days to cover
Days to cover
1.6d
Short-squeeze score
39 / 100
Insider activity
2 metricsNet insider buying (90D)
−$1,431
Insider-sentiment score
38 / 100
Risk flags
1 metricsGoing concern
—